As treatment control, an additional group of mice was included receiving the soluble TNF-receptor-Ig fusion protein etanercept (ETN; 2mg/kg, 3 times/week, i.p.), a TNF-alpha antagonist approved for the treatment of RA and known to potently decrease incidence and severity of CIA (41, 42). This evidence concerns the gene TNF and rheumatoid arthritis.